Updated:
Rapha Capital Management
Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities | We use our unique abilities to identify at the...
Rapha Capital Management
Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities | We use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities
General information
Firm type
Private Equity
Year founded
2018
Location
Region
North America
Country
United States
City
Surfside
Corporate office
9511 Collins Avenue, #1403, Surfside, FL 33154, United States
Principals
Kevin Slawin
Founder and Managing Partner
Sector focus
Frequently asked questions
How does Rapha Capital source proprietary deal flow?
Rapha Capital co-invests in and operates out of K2 Biolabs, a Houston-based biotech co-working facility co-founded by Kevin Slawin. This physical infrastructure gives Rapha Capital early visibility into startup formation, enabling it to seed companies before traditional venture capital processes engage. Slawin's operating companies — Ponce Therapeutics and DELiver Therapeutics — also generate pipeline through internal R&D programs.
Is Rapha Capital structured as a venture firm or an incubator?
Rapha Capital operates as a private equity firm running 13 managed investment entities and multiple fund vehicles, including Rapha Capital BioVentures Fund I and Rapha Capital PE Life Sciences Fund VI. Functionally, it blends venture investing with a biotech studio model because Slawin personally co-founds and incubates several portfolio companies through K2 Biolabs.
What investment stages does Rapha Capital typically target?
Rapha Capital invests primarily at the seed and early institutional stages. Companies like PrintBio and Phoenix SENOLYTIX entered the portfolio before or during preclinical development, and Slawin's thesis emphasizes identifying disruptive biotechnologies before they surface in broader venture pipelines.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: